Ten Years of Progress in Renal Cell Carcinoma

Restricted access

Eric Jonasch, MD, is Associate Professor in the Department of Genitourinary Medicine at The University of Texas MD Anderson Cancer Center. He completed his medical education at McGill University in Montreal, Canada, and his fellowship at the Beth Israel Deaconess Medical Center. Dr. Jonasch is board certified in medical oncology, hematology, and internal medicine by the American Board of Internal Medicine, and in oncology and medicine by the Royal College of Physicians & Surgeons of Canada. His professional memberships include the American Association for Cancer Research and ASCO. He is a member of the NCCN Guidelines Panel for Kidney and Testicular Cancers. Dr. Jonasch is also a medical advisor for the Kidney Cancer Association and the von Hippel-Lindau Family Alliance.

Dr. Jonasch has authored more than 80 peer-reviewed articles, several book chapters, and a textbook on kidney cancer, and has presented at numerous national and international conferences.

Dr. Jonasch’s research interests include renal cell carcinoma, von Hippel-Lindau disease, and defining the determinants of response and resistance to antiangiogenic agents. He is principal investigator of a National Institutes of Health Roadmap initiative grant, and several industry and institutionally sponsored research grants.

Robert J. Motzer, MD, is a medical oncologist at Memorial Sloan-Kettering Cancer Center, with a primary area of expertise in kidney (renal cell carcinoma) and testicular cancer (germ-cell tumor), and has led more than 50 clinical trials for these cancers both nationally and internationally. Through this research, he helped identify 3 targeted antiangiogenesis drugs that serve as effective first- or second-line treatments for patients with advanced kidney cancer. Dr. Motzer helped develop a system to aid in predicting outcomes for patients taking medications for advanced kidney cancer—a tool now widely applied by physicians around the world to direct the care of patients.

In addition to publishing more than 300 original articles, scientific reviews, chapters, and abstracts, Dr. Motzer has lectured on kidney and testicular cancer care internationally and worked to improve cancer care through health care policy and advocacy activities. Dr. Motzer chairs the NCCN Guidelines Panels for Kidney and Testicular Cancers.

Dr. Motzer graduated from the University of Michigan Medical School and has received the Career Development Award from the NIH and the Willet F. Whitmore Award for Clinical Excellence from Memorial Sloan-Kettering.

The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.

  • 1

    Motzer RJ, Escudier B, Oudard S. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449456.

    • Search Google Scholar
    • Export Citation
  • 2

    Motzer RJ, Hutson TE, Tomczak P. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115124.

  • 3

    Hudes G, Carducci M, Tomczak P. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:22712281.

  • 4

    Sternberg CN, Davis ID, Mardiak J. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:10611068.

    • Search Google Scholar
    • Export Citation
  • 5

    Rini BI, Escudier B, Tomczak P. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2012;378:19311939.

    • Search Google Scholar
    • Export Citation
  • 6

    Escudier B, Eisen T, Stadler WM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125134.

  • 7

    Escudier B, Pluzanska A, Koralewski P. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:21032111.

    • Search Google Scholar
    • Export Citation
  • 8

    Varela I, Tarpey P, Raine K. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011;469:539542.

    • Search Google Scholar
    • Export Citation
  • 9

    Dalgliesh GL, Furge K, Greenman C. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010;463:360363.

    • Search Google Scholar
    • Export Citation
  • 10

    Monzon FA, Alvarez K, Peterson L. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol 2011;24:14701479.

    • Search Google Scholar
    • Export Citation
  • 11

    Klatte T, Rao PN, de Martino M. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009;27:746753.

    • Search Google Scholar
    • Export Citation
  • 12

    Latif F, Tory K, Gnarra J. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:13171320.

  • 13

    Figlin RA, Hutson TE, Tomczak P. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2008;26(Suppl):Abstract 5024.

    • Search Google Scholar
    • Export Citation
  • 14

    Heng DY, Xie W, Regan MM. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:57945799.

    • Search Google Scholar
    • Export Citation
  • 15

    Motzer RJ, Bacik J, Murphy BA. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289296.

    • Search Google Scholar
    • Export Citation
  • 16

    Rini BI, Cohen DP, Lu DR. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103:763773.

    • Search Google Scholar
    • Export Citation
  • 17

    Zurita AJ, Jonasch E, Wang X. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23:4652.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 112 96 3
PDF Downloads 13 9 1
EPUB Downloads 0 0 0